Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
This study is a longitudinal and cross-sectional evaluation of patients with Chronic
 Granulomatous Disease (CGD) who received or are receiving hematopoietic cell transplantation
 (HCT) for their disease under a variety of protocols used by participating institutions
 compared to a control non-HCT group receiving standard care. Investigators at multiple
 centers caring for patients with CGD in North America and 3 centers in Europe will
 participate. Patients with CGD will have been treated according to institutional practice and
 protocols. Investigators will enroll these patients as subjects in this protocol. This study
 will investigate which patients benefit most from HCT, and what types of transplants are
 optimal for patients with CGD, in the context of overall outcomes in CGD patients with and
 without transplant.
This study is a longitudinal and cross-sectional evaluation of patients with Chronic
 Granulomatous Disease (CGD) who received or are receiving hematopoietic cell transplantation
 (HCT) for their disease under a variety of protocols used by participating institutions
 compared to a control non-HCT group receiving standard care. Investigators at multiple
 centers caring for patients with CGD in North America and 3 centers in Europe will
 participate. Patients with CGD will have been treated according to institutional practice and
 protocols. Investigators will enroll these patients as subjects in this protocol. This study
 will investigate which patients benefit most from HCT, and what types of transplants are
 optimal for patients with CGD, in the context of overall outcomes in CGD patients with and
 without transplant.
-  Both HCT and non-HCT subjects must be over the age of 2 and actively enrolled and
 receiving treatment under a CGD protocol at NIAID.